Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice.
To investigate the efficacy and safety of gatifloxacin (400mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N=149, mean 45.8+/-13.3 years) and cystitis (N=304, mean 53.8+/-14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis.
Lee
Sang Don
SD
Department of Urology, Pusan National University Hospital, 1-10 Ami-dong, Seo-gu, Busan, South Korea.
Lee
Seung Ju
SJ
Hwang
Tae Kon
TK
Yoon
Duck Ki
DK
Lee
Kyu Sung
KS
Sung
Luck Hee
LH
Choo
Myung Soo
MS
Shim
Bong Suk
BS
Cho
In Rae
IR
Kim
Min Eui
ME
Ryu
Soo Bang
SB
Kim
Chul Sung
CS
Kim
Young Gon
YG
Kim
Chun Il
CI
Rhew
Hyun Yul
HY
Kim
Myung Hoon
MH
Cho
Yong-Hyun
YH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects* / Q000627:therapeutic use*; D000077734:Gatifloxacin; D006801:Humans; D007723:Korea; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology
D024841:Fluoroquinolones; D000077734:Gatifloxacin